Brief: Hepion Pharmaceuticals Completes First Cohort Enrollment In Phase 2A 'Ambition' Clinical Trial
10/11/2020 15:39
Nov 10 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS INC - COMPLETES FIRST COHORT
ENROLLMENT
IN PHASE 2A 'AMBITION' CLINICAL TRIAL
* HEPION PHARMACEUTICALS INC - HAS ENROLLED THE LAST
PATIENT IN
THE 75 MG CRV431 COHORT OF ITS PHASE 2A ‘AMBITION’ CLINICAL
TRIAL.
Source text - https://bit.ly/3li2at7
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement